Le Cong,

Dr. Cong recently started his group at Stanford in the Department of Pathology and Genetics to pursue novel technology for scalable genetic and epigenetic engineering, as well as computational approaches for single-cell tracking in space and time, with a focus on studying cancer immunology and immunological disorders. He obtained his BS with highest honor from Tsinghua University studying Electronic Engineering and then Biology, and his Ph.D. from Harvard Medical School co-advised by Drs. Feng Zhang and George Church. He completed doctoral work primarily in Dr. Feng Zhang’s laboratory, where he published seminal study on CRISPR/Cas9 for gene editing. He has obtained over 16 issued patents as co-inventor, and subsequently modified the CRISPR system for gene and cell therapy, leading to one of the first FDA-approved clinical trial employing viral delivery of CRISPR/Cas9 technology in vivo. His postdoctoral work applied single-cell RNA-seq to understand cancer biology under Dr. Aviv Regev at the Broad Institute in collaboration with Dr. Tyler Jacks and Vijay Kuchroo. Dr. Cong was a Howard Hughes Medical Institute (HHMI) International Fellow, a Cancer Research Institute (CRI) Irvington Fellow, and was selected in Forbes 30 Under 30 Asia list of young innovators, and the MIT TechnologyReivew TR35 China list.